dsip extension nysed Event Calendar X-line Updates: New DAQ Modules

Priority Applications (3) Applications Claiming Priority (4) Publications (1) Family ID=50100453 Family Applications (1) Country Status (5) Cited By (2) Families Citing this family (3) Citations (3) 2013 2013-09-27 WO PCT/US2013/062199 patent/WO2014052766A1/en not_active Ceased 2013-09-27 US US14/038,973 patent/US9051351B2/en active Active 2015 2015-03-26 SA SA515360200A patent/SA515360200B1/en unknown 2015-03-26 IL IL237966A patent/IL237966A0/en unknown 2015-04-14 ZA ZA2015/02504A patent/ZA201502504B/en unknown

2is a graph of ABR at different doses: 9 mg/kg (201), 10 mg/kg (203), 11 mg/kg (205), 12 mg/kg (207), and 15 mg/kg (209)

No Severe Effects in Controlled Observations: Intravenous infusion of up to 20 mg of BPC-157 in 2 healthy adults showed no adverse effects and was well-tolerated, with no measurable changes across heart, liver, kidney, thyroid, or blood glucose markers

Conclusion The BPC-157 FDA approval status 2026 is unambiguous at the approval level: BPC-157 is not FDA approved, has no active IND, and has no registered human clinical trials

#MUSE #IHC #Immunofluorescence #SignalAmplification #ProteinDetection #Biotech #LifeSciences #Biomarkers #SpatialBiology #Neuroscience To view or add a comment, sign in Exciting to see MUSE signal amplification technology enabling clearer, more sensitive detection in complex tissue